Goldman Sachs Group Inc.’s private equity arm has agreed to buy a controlling stake in Norgine BV from the specialty pharmaceutical company’s founding Stein family.
The deal was announced in a statement Thursday that confirmed an earlier Bloomberg News report. Financial terms weren’t disclosed. The purchase values Amsterdam-based Norgine at about 1.8 billion euros ($1.9 billion), according to people familiar with the matter.
Norgine, which traces its roots back more than a century, manufactures products including Movicol, Moviprep and Plenvu, drugs used in the treatment of gastrointestinal disorders. Goldman Sachs plans to grow the business in part through mergers and acquisitions.
Read more: BNN Bloomberg